NanoSyrinx

NanoSyrinx is a biotechnology company developing a novel drug delivery platform based on engineered protein 'nanosyringes'. Founded in 2020 as a spin-out from the University of Warwick, NanoSyrinx aims to revolutionize intracellular delivery of therapeutic proteins and peptides. The company's technology is derived from naturally occurring bacterial injection systems, which have been adapted to deliver biological payloads directly into the cytosol of targeted cells. This approach offers potential advantages over existing delivery methods, including improved efficacy, reduced side effects, and the ability to reach previously inaccessible intracellular targets.

The nanosyringe platform is highly customizable, allowing for the delivery of various peptide and protein payloads. NanoSyrinx's technology has applications across both in vivo and in vitro biology, with initial focus on cell and gene therapy, particularly in areas such as immuno-oncology. The company utilizes synthetic biology and molecular biology techniques to manipulate the payload platform, improve delivery yields, and reduce toxicity. As of 2024, NanoSyrinx is in the discovery stage, working on proof-of-concept studies and preclinical development candidates for both ex vivo and in vivo therapeutic applications.

NanoSyrinx has made significant progress in developing its technology, including establishing bioassays to demonstrate payload delivery and advancing efforts in manufacturing these unique bacterial injectors. The company is working on scaling up its nanosyringe manufacturing pipeline and conducting safety and efficacy studies. As of January 2024, NanoSyrinx employed 14 full-time staff and was recognized as an AbbVie Golden Ticket winner in 2022 and a PwC Life Sciences Future50 company in 2023.